Tedaviye dirençli depresyonda ketamin infüzyonu: Bir vaka sunumu ve literatürün kısa gözden geçirilmesi 
INTRODUCTION
An abundant number of patients diagnosed with major depressive disorder exhibit poor or no response to conventional antidepressants and they are identified to have treatment-resistant depression (1) . The rapid onset of antidepressant effect generated by subanesthetic intravenous ketamine provides a hope. Ketamine has been used clinically as a dissociative anesthetic for more than three decades and is considered as a noncompetitive glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist (2) . Recent observations in clinical settings imply that at subanesthetic doses, ketamine produces therapeutic effects in depressed patients (3) . The antidepressant effects were characterized by a rapid onset of action (4) , lasted for a time, and observed after a single dose, and was effective in treatment-resistant patients (5) .
Here, we report a case with treatment-resistant depression on which intravenous ketamine infusions led to treatment response and a beneficial effect on suicidal ideation.
CASE
The subject is a 48-year-old male teacher with the diagnosis of major depressive episode and had proven to be treatment-resistant despite use of at least five different antidepressants. He did not respond to augmentations either with lithium or thyroid hormone that were given in adequate doses for a relevant duration. He had his first depressive episode when he was in his mid-twenties, and the current episode was his sixth episode, which has lasted for ten months. He did not report any psychiatric or general medical comorbidity. He never had symptoms of mania or psychotic features. He denied use of any illegal substance or alcohol.
He had two prior suicide attempts three and five years ago with overdosing of psychiatric medications. Besides anhedonia, depressed mood, psychomotor retardation, energy loss, and insomnia, he had plans for another suicide attempt. Electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) had also been performed on the current episode without any response. He also had six sessions of cognitive behavioral therapy but did not want to continue due to his belief that those treatments would not work on him. Due to inadequate symptom control with pharmacotherapy, the patient has been informed about the off-label therapeutic use and possible side effects of ketamine infusion, and then he gave written informed consent.
ECG, EEG, cranial imaging, chest X-ray, and blood analysis were performed. All have revealed normal results. In this particular case we observed that repeated-dose ketamine has caused a significant reduction in depressive symptoms and the improvement in depressive symptoms remained even three weeks after the last (fifth) injection of it.
Although several studies showed that ketamine promotes a rapid antidepressant effect, it is important to perceive that after a single dose, effect gradually fades in 3-7 days (12).
Further investigation showed that the time until relapse is varying between 6 days to greater than 3 months. Some not necessitate the presence of active drug levels (19) . The rapidity of ketamine action implies that major symptoms of depression can be without abundant structural plasticity or circuit rewiring. The effect is estimated to be by molecular cascades that promote synaptic plasticity and dendritic spine maturation in critical brain regions (20) .
There is currently open-label evidence to imply benefit of oral ketamine (21) and sublingual administration (22); however, efficacy data is lacking. Oral ketamine, however, has limited bioavailability, and therefore other routes of administration are being studied, involving intramuscular and intranasal routes (23) .
In most trials ketamine is administered intravenously (i.v) at the dose of 0.5 mg/kg along 40 minutes, vital signs and side effects being continuously monitored (10, 24, 25) . Some authors suggest that repeated administrations, better than a single one, may be needed to obtain stable remission (26, 27) .
In trials wherein protocols with multiple administrations are adopted, ketamine is usually administered at 0.5 mg kg every other day until a maximum of 6 infusions along two weeks of treatment (28) .
The majority of studies reported no serious adverse events. One study reported cardiovascular side-effects in 2 of 47 patients who received ketamine (refractory hypertension in one case, hypotension and bradycardia in the other) (10).
In the meta-analysis of McGirr et al., drop-out rates were used as a proxy for tolerability. 13.3% of the ketamine receiving patients dropped out compared to 7.4% of patients who were on control interventions (8) . A recent study 
CONCLUSION
This case suggests that intravenous administration of ketamine may be efficacious for the rapid relief of symptoms in unipolar depression and may also decrease suicidal ideation. Although additional research is required to determine optimal dosing schedules, administration routes and the potential efficacy of glutamatergic agents, NMDA agents warrant further investigation as part of strategies dedicated to diminish suicide deaths.
